Composition: Bempedoic acid 180 mg
Form: Film-coated tablets
Indications: Reduction of the risk of myocardial infarction and coronary revascularization in adults who cannot take recommended statin therapy, as well as reduction of LDL-C in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia.
Contraindications: Hypersensitivity to bempedoic acid or any excipient.
Dosage: One 180 mg tablet orally once daily, with or without food. Lipid profile assessment is recommended 8 to 12 weeks after treatment initiation.
Side effects: Upper respiratory tract infections, muscle spasms, hyperuricemia, back pain, abdominal pain or discomfort, bronchitis, pain in extremities, anemia, elevated liver enzymes.
Interactions: Avoid concomitant use with simvastatin at doses above 20 mg and pravastatin at doses above 40 mg.
Warnings: Serum uric acid should be monitored according to clinical indications during therapy. Treatment should be discontinued at the first signs of tendon rupture.
Age restrictions: For adult patients only.
Pregnancy: Discontinue treatment if pregnancy is confirmed unless the expected benefit outweighs the potential risk to the fetus. Breastfeeding is not recommended during therapy.
Country of origin: Bangladesh
Manufacturer: Incepta Pharmaceuticals Ltd.
Storage conditions: Store below 30°C, protected from light, out of reach of children.